Pharmacokinetics and toxicity of idarubicin in the rat

被引:0
作者
Kuhlmann, O
Hofmann, S
Weiss, M [1 ]
机构
[1] Univ Halle Wittenberg, Dept Pharmacol, Sect Pharmacokinet, D-06097 Halle Saale, Germany
[2] Univ Halle Wittenberg, Dept Cardiothorac Surg, D-06097 Halle Saale, Germany
关键词
idarubicin; idarubicinol; rat; lung; pharmacokinetics;
D O I
10.1007/BF03226374
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was designed to examine the pharmacokinetics and toxicity of idarubicin (IDA) in rats. In two groups of rats IDA was infused either into the V. iugularis interna or into the A. carotis communis, respectively. The venous plasma concentration of IDA and its primary metabolite idarubicinol (IDOL) were measured up to 48 hours by high - performance liquid chromatography (HPLC) with fluorescence detection. The weights of the rats and the levels of haemoglobin, leukocytes, and thrombocytes were recorded. The plasma concentration - time data were analysed, assuming a biexponential disposition curve, both by the traditional (two - stage) method and by population pharmacokinetic modelling. The basic pharmacokinetic parameters clearance (CL = 27.0 ml min(-1)), mean disposition residence time (MDRT = 519.2 min), and volume of distribution at steady state (V-ss = 12.51) were estimated for IDA. The mean residence time (MRT) of the generated IDOL was 2982.5 min. No significant differences between pre- and postpulmonal injection were found in the pharmacokinetics and pharmacodynamics of IDA. The mean survival time of 13.3 days is attributed to a severe myelosuppression.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 50 条
  • [41] The influence of endotoxemia on the pharmacokinetics and the electroencephalographic effect of propofol in the rat
    De Paepe, P
    Belpaire, FM
    Van Hoey, G
    Boon, PA
    Buylaert, WA
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (01) : 104 - 114
  • [42] Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite - A comparison of bolus versus 2 h infusion during a 3 day course
    Eksborg, S
    Bjorkholm, M
    Hast, R
    Fagerlund, E
    ANTI-CANCER DRUGS, 1997, 8 (01) : 42 - 47
  • [43] Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog -: Interspecies relationship comparing with human pharmacokinetics
    Påhlman, I
    Kankaanranta, S
    Palmér, L
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2001, 51 (02): : 134 - 144
  • [44] A Pharmacokinetic Study of Idarubicin in Japanese Patients With Malignant Lymphoma: Relationship With Leukocytopenia and Neutropenia
    Toshihiro Fukushima
    Taro Yamashita
    Nobuyuki Goto
    Takanori Ueda
    Ken-ichi Okabe
    Yasunobu Kuraishi
    Ryuzo Ohno
    Akio Urabe
    Makoto Ogawa
    International Journal of Hematology, 2001, 74 : 297 - 302
  • [45] A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: Relationship with leukocytopenia and neutropenia
    Fukushima, T
    Yamashita, T
    Goto, N
    Ueda, T
    Okabe, K
    Kuraishi, Y
    Ohno, R
    Urabe, A
    Ogawa, M
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2001, 74 (03) : 297 - 302
  • [46] Pharmacokinetics of Vicenin-2 in Rat after Intravenous Administration
    Li, Fang
    Chen, Yuyan
    Liu, Jiawen
    Jin, Yongxi
    Shao, Lingjiu
    LATIN AMERICAN JOURNAL OF PHARMACY, 2019, 38 (11): : 2127 - 2130
  • [47] Pharmacokinetics of pinokalant, a new nonselective cation channel blocker in the rat
    Leusch, A
    Eichhorn, B
    Busch, U
    Ensinger, HA
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2001, 51 (12): : 947 - 954
  • [48] Pharmacokinetics of kanamycin in the developing rat
    Henley, CM
    Weatherly, RA
    Ou, CN
    Brown, RD
    HEARING RESEARCH, 1996, 99 (1-2) : 85 - 90
  • [49] Characterization of the pharmacokinetics of dioscin in rat
    Li, K
    Tang, YB
    Fawcett, JP
    Gu, JK
    Zhong, DF
    STEROIDS, 2005, 70 (08) : 525 - 530
  • [50] Pharmacokinetics of Plasmid DNA in the Rat
    Brett E. Houk
    Robin Martin
    Günther Hochhaus
    Jeffrey A. Hughes
    Pharmaceutical Research, 2001, 18 : 67 - 74